Cornel Iridoid Glycoside, a promising agent for AD therapy, inhibits tau hyperphosphorylation via regulating cross-talk between GSK-3β and PP2A signaling (Yang et al., 2018a). This evidence concerns the gene MAPT and Alzheimer disease.